Resources

LBIC announces that its new space in the Apex facility has reached over 50% occupancy just six months after launch, with the addition of Bind Research, its first non-profit tenant, and Twig Bio, a sustainable biotech company.

A London-based biotech firm that aims to improve infant health with its research into the microbiomes of breast milk has raised £2.5 million.

NRG Therapeutics, an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B financing.

In this blog, Paul Nelson, Corporate Foreign Exchange at Moneycorp, outlines the unpredictability of global markets and what this means for BIA members. 

In this blog, Elisa Petris, Partner at Syncona Investment Management Limited, and Emma Johnson, Senior Investment Manager – Life Sciences at the British Business Bank, write in their capacity as Co-founders of Invest in Equity. They share why they launched the initiative, the urgency of improving gender diversity in life science investment, and how a more inclusive ecosystem can drive stronger returns and better outcomes for patients.

In this blog, Alastair Hall, Hub Eurasia Director, FI Group, explores how Innovate UK Innovation Loans are helping biotech SMEs bridge the gap between research and commercialisation. He highlights why they are most effective when combined with other funding sources to build a resilient strategy for growth.

BIA member Charm Therapeutics, co-founded by Nobel laureate David Baker, has raised an $80 million Series B to move its AI-designed cancer drug into the clinic early next year.

Roche’s Genentech unit has handed over $20 million in upfront cash for the license to Omass Therapeutics’ preclinical inflammatory bowel disease (IBD) program.

In the third part of our series on Industrial Strategy, Lewis Miles and Maddie Cass provide a deep dive into the Digital and Technologies Sector Plan, analysing how these policies aim to foster growth in the UK's life sciences and engineering biology sectors. We also look forward to strengthening relations and gaining key insight from our US sister organisation with BIO's upcoming UK visit.

Research conducted by Pioneer Group in collaboration with Beauhurst into the UK life sciences landscape reveals a growing trend of investment into more mature companies.

LIfT BioSciences ('LIfT' or 'the Company')today announces a grant of €12 million has been awarded from Ireland's Disruptive Technologies Innovation Fund

In my final summer update as BIA CEO, I reflect on 12 amazing years and look ahead to my new role as Executive Chair of the Office for Life Sciences. This week we’ve also published our latest finance report, and we’re hiring - so if you’re looking for your next challenge, now’s the time to join Team BIA.

The UK government has officially launched its landmark Life Sciences Sector Plan, backed by over £2 billion in public funding and spearheaded by the Department for Science, Innovation and Technology, Business and Trade, and Health and Social Care.

The BioIndustry Association today publishes new data revealing that the UK’s life sciences sector attracted £1.23 billion in venture capital (VC) investment in the first half of 2025, thereby putting it on track to match or surpass 2024’s total.

Brandon Capital, Australasia’s leading life sciences venture capital firm, today announced the final close of its sixth fund at A$439 million.

A response from Discovery Park’s CEO, Mayer Schreiber, in light of the Government’s Life Science Sector Plan.

Myricx Bio announces that it has been awarded the Cancer Research Horizons Start-Up Achievement Recognition Award for 2025, which it received at a ceremony in London last night.

Today, the British Business Bank has announced a new £400 million Investor Pathways Capital initiative, which will support diverse and emerging fund managers across the economy and make it easier for new entrants, particularly those from underrepresented groups, to break into venture capital.